ライフサイエンスコーパス: diclofenac

1 eved from rats receiving only caspofungin or diclofenac.

2 , 48 min with flurbiprofen, and 0.8 min with diclofenac.

3 itor etoricoxib versus the traditional NSAID diclofenac.

4 ited by miconazole and, to a less extent, by diclofenac.

5 % CI 0.81-1.11) for etoricoxib compared with diclofenac.

6 itor etoricoxib versus the traditional NSAID diclofenac.

7 ting from 2 weeks' ingestion of slow-release diclofenac.

8 among all lumiracoxib dosages and similar to diclofenac.

9 arable efficacy and superior tolerability to diclofenac.

10 s entered the trial, and 110 received rectal diclofenac.

11 rybdotoxin, or the cyclooxygenase inhibitor, diclofenac.

12 e, 6-keto PGF(1alpha), that was abolished by diclofenac.

13 l and engineered transformation reactions of diclofenac.

14 n reactions within the environmental life of diclofenac.

15 he predominant cause of adverse reactions to diclofenac.

16 carbon and nitrogen isotope measurements of diclofenac.

17 reater than the proposed EQS of 100 ng/L for diclofenac.

18 vents were similar for etoricoxib (0.30) and diclofenac (0.32).

19 events with etoricoxib than there were with diclofenac (0.57, 0.45-0.74; p<0.0001); there was no dif

20 ulcer) were lower with etoricoxib than with diclofenac (0.67 vs 0.97 per 100 patient-years; hazard r

21 atients were discharged on the same day with diclofenac, 0.2% glyceryl-trinitrate ointment, lactulose

22 Twelve analogues of diclofenac (1), a nonsteroidal antiinflammatory drug and

23 Rats were treated orally with diclofenac (10-100 mg/kg) and killed after 1-24 hours, a

24 Diclofenac (100 muM) inhibited KCNQ5 channels, reducing

25 I also occurred in 1 of 9480 patients taking diclofenac (11 of 100,000; 95% CI, 4-24), 1 of 133 patie

26 risons of etoricoxib (60 or 90 mg daily) and diclofenac (150 mg daily) in 34 701 patients with osteoa

27 gned to etoricoxib (60 mg or 90 mg daily) or diclofenac (150 mg daily).

28 y assigned to etoricoxib (60 or 90 mg qd) or diclofenac (150 mg qd).

29 Two days later, a single intravenous dose of diclofenac (2 mg/kg) (treated animals) was given, and af

30 uoromethyl)phenyl]amino}nicotinic acid], and diclofenac [2-(2-(2,6-dichlorophenylamino)phenyl)acetic

31 star rats (8 weeks old) were pretreated with diclofenac (20 mg/kg, s.c.) or saline, followed by intra

32 were randomized to one of two groups, 75 mg diclofenac + 200 microg misoprostol twice daily or 1,000

33 25 mg of rofecoxib once daily, and 50 mg of diclofenac 3 times daily.

34 ut dextromethorphan O- and N-demethylations, diclofenac 4'-hydroxylation, and phenacetin O-deethylati

35 ere amoxicillin-clavulanate (21 of 96; 22%), diclofenac (6%), azathioprine (4%), infliximab (4%), and

36 wice daily or 400 mg once daily; placebo; or diclofenac 75 mg twice daily.

37 ted aspirin two hours before delayed-release diclofenac (75 mg twice daily)

38 age, 26 y; 42% female) were given the NSAID diclofenac (75 mg twice daily) plus omeprazole (20 mg on

39 rofen, 800 mg 3 times per day (n = 1985); or diclofenac, 75 mg twice per day (n = 1996).

40 physiological characteristics and effects of diclofenac, a known KCNQ channel activator, on human KCN

41 ib, a COX-1 sparing inhibitor of COX-2, with diclofenac, a non-specific COX inhibitor.

42 ortantly, inhibition of PGE2 production with diclofenac, a nonselective COX inhibitor, resulted in re

43 Diclofenac, a nonsteroidal anti-inflammatory drug inhibi

44 f this study was to evaluate the efficacy of diclofenac, a potent NSAID, in the the immediate symptom

45 Diclofenac accumulated in a concentration- and time-depe

46 In this study, the THz spectra of two diclofenac acid polymorphs were obtained by THz spectros

47 ither diclofenac sodium solution (0.3 mg) or diclofenac acid suspension (10 mg) prepared in 0.1 mL ba

48 se distribution or depot compartment for the diclofenac acid suspension in the posterior segment.

49 and the retina-choroid even on day 21 after diclofenac acid suspension injection, with retina-choroi

50 Diclofenac acid was prepared and characterized in a susp

51 Diclofenac acid with an approximate 5-mum particle size

52 oosing a less soluble form of a drug such as diclofenac acid, vitreous elimination half-life can be p

53 bolites may lead to higher levels of protein-diclofenac adducts and subsequently hepatotoxicity.

54 lity by using immunohistochemistry to detect diclofenac adducts.

55 c acid, and a phenyl acetic acid derivative, diclofenac, also are low-potency (EC(50) = 80 muM to 2.1

56 ancreatitis (11%), of whom 7 received rectal diclofenac and 17 received placebo (P < 0.05).

57 ticular (15)N corroborated transformation of diclofenac and bentazone.

58 rieved from rats that were treated with both diclofenac and caspofungin contained significantly fewer

59 Lumiracoxib tolerability was superior to diclofenac and comparable to placebo.

60 Diclofenac and etoricoxib accounted for one-third of tot

61 aluate the approach for two pharmaceuticals (diclofenac and fluoxetine) and one personal care product

62 IgEs to most frequently used NSAIDs such as diclofenac and ibuprofen are urgently needed.

63 lorobenzamide (BAM), and the pharmaceuticals diclofenac and ibuprofen was released into a mesoscale a

64 Complete relief of pain was obtained in 21 diclofenac and in 7 placebo patients; progression to acu

65 scopically in 33 (15%) patients treated with diclofenac and in eight (4%) in the celecoxib group (p<0

66 (similar range as potent inhibitors such as diclofenac and indomethacin in the same experimental con

67 er currently approved therapeutics including diclofenac and minocycline.

68 Enteropathy is a frequent complication of diclofenac and other nonsteroidal anti-inflammatory drug

69 receptor antagonist and clinically by use of diclofenac and pancreatic duct stenting.

70 In this instrumental variable analysis, diclofenac and rofecoxib had the least favorable benefit

71 superiority to the cyclooxygenase inhibitors diclofenac and rofecoxib.

72 the most recalcitrant micropollutants (i.e., diclofenac and targeted sulfonamides).

73 nd rapidly transferred to the sorbent (e.g., diclofenac) and (2) more hydrophobic chemicals accumulat

74 onsteroidal antiinflammatory drugs (NSAIDs) (diclofenac) and novel COX-2-selective inhibitors (NS-398

75 n, 5-fold higher for the 4'-hydroxylation of diclofenac, and 3-fold higher for the omega-1 hydroxylat

76 ncentrations of carbendazim, clarithromycin, diclofenac, and diuron exceed levels of ecotoxicological

77 etylsalicylic acid, acetaminophen, atenolol, diclofenac, and ibuprofen were tested as target analytes

78 steroidal antiinflammatory drugs (celecoxib, diclofenac, and indomethacin), a p38 MAPK inhibitor, SB2

79 YP2C9*5 were carried out using (S)-warfarin, diclofenac, and lauric acid as substrates.

80 Cimetidine, diclofenac, and miconazole, known inhibitors of CYP450 2

81 in, carbamazepine, moxifloxacin, cephalexin, diclofenac, and nitrofurantoin.

82 anic acids (sulindac, ibuprofen, ketoprofen, diclofenac, and norfloxacin) were infused into rats with

83 used pharmaceutical compounds (S-ibuprofen, diclofenac, and S-warfarin) by one of the major drug-met

84 uprofen but not rofecoxib, acetaminophen, or diclofenac antagonizes the irreversible platelet inhibit

85 ces were used to investigate polyclonal anti-diclofenac antibodies recognition and reversibility usin

86 Celecoxib, rofecoxib, and diclofenac are clinically used cyclooxygenase-2 (COX-2)

87 We propose that residues of veterinary diclofenac are responsible for the OWBV decline.

88 cy that was clinically comparable to that of diclofenac, as assessed by all 3 primary end points acco

89 ug-like molecules, including salicylates and diclofenac, as MR1-binding ligands.

90 ruct the biosensor, the amino-functionalized diclofenac binding aptamer (DBA) was covalently immobili

91 that the nonsteroidal anti-inflammatory drug diclofenac binds a single monomer of native huPGHS-2, ha

92 clofenac with murine COX-2 demonstrates that diclofenac binds to COX-2 in an inverted conformation wi

93 proxen, nonylphenol, octylphenol, ibuprofen, diclofenac, bisphenol A, and triclosan.

94 The structure of the anti-inflammatory drug diclofenac bound in the active site of rabbit microsomal

95 ete loss of activity toward (S)-warfarin and diclofenac, but preservation of pyrene metabolism.

96 Here we quantified the uptake of diclofenac by the fathead minnow (Pimephales promelas) f

97 ketamine, norketamine, O-desmethyltramadol, diclofenac, carbamazepine, and methoxetamine were not su

98 apped reactive metabolites of acetaminophen, diclofenac, carbamazepine, clozapine, p-cresol, 4-ethylp

99 It was found that the wastewater borne MPs diclofenac, carbamazepine, sulfamethoxazole, acesulfame,

100 The proximity of the diclofenac carboxylate to the side chain of D290 togethe

101 Neither flurbiprofen nor diclofenac changed the EPR line width when added after p

102 hannels endogenously, and their responses to diclofenac closely resembled those of the overexpressed

103 Acetaminophen, diclofenac, codeine, ampicillin, tetracycline, erythromy

104 ver in hippocampus, while pre-treatment with diclofenac completely prevented these neurochemical resp

105 Nitrosothiol esters of diclofenac comprise a novel class of NO-donating compoun

106 -1) for MCPA, 2,4-D, mecoprop, atenolol, and diclofenac, corresponding to half-lives of 0.6-6.3 h, de

107 This report indicates that diclofenac could be useful in combination therapy with c

108 The first one is a molecular probe, diclofenac, coupled with an arylamine onto which a speci

109 tection of the pharmaceutical micropollutant diclofenac (DCF) in water.

110 king the nonsteroidal anti-inflammatory drug diclofenac (DCF) presented with acute Coombs-positive he

111 emove an anionic pharmaceutical product, the diclofenac (DCF), recognized as a recalcitrant compound

112 The affinity of the anionic pharmaceutical, diclofenac (DCF), to the composite was high and did not

113 by investigating the metabolism of the drugs diclofenac (DCF), troglitazone (TGZ), and raloxifene, fo

114 mical aptasensor for the detection of sodium diclofenac (DCF).

115 lonN = -7.1 per thousand), whereas reductive diclofenac dechlorination was associated with significan

116 is stated that etoricoxib is not inferior to diclofenac, defined as an upper boundary of less than 1.

117 analysis bears potential not only to detect diclofenac degradation, but even to distinguish both tra

118 -specific isotope analysis (CSIA) may detect diclofenac degradation.

119 This study showed that diclofenac delayed both T(max) and T1/2.

120 The substantial quantities of diclofenac delivered locally in hyaluronan may exhibit a

121 At equimolar oral doses, S-NO-diclofenac derivatives (20a-21b) displayed rat antiinfla

122 All tested S-NO-diclofenac derivatives (20a-21b) were gastric-sparing in

123 All S-NO-diclofenac derivatives acted as orally bioavailable prod

124 nsteroidal anti-inflammatory drugs (NSAIDs), diclofenac (Dic) and naproxen (Nps), were studied by X-r

125 ministration of rofecoxib, acetaminophen, or diclofenac did not affect the pharmacodynamics of aspiri

126 Celecoxib, but not rofecoxib or diclofenac, dramatically enhanced KCNQ (K(v)7) potassium

127 r etoricoxib than with the traditional NSAID diclofenac due to a decrease in uncomplicated events, bu

128 Inhibition of PGE2 synthesis by diclofenac enhanced collagen production in skin organ cu

129 t a causal role for drug adduct formation in diclofenac enteropathy.

130 A series of novel diclofenac esters containing a nitrosothiol (-S-NO) moie

131 Three drugs (rofecoxib, diclofenac, etoricoxib) ranked consistently highest in t

132 The drugs diclofenac, fluoxetine, and gemfibrozil belong to differ

133 e and uptake of (14)C-labeled carbamazepine, diclofenac, fluoxetine, and orlistat in soil-earthworm s

134 aged 22-77 (mean, 52) years who were taking diclofenac for 0.3-20 (mean, 4) years without developing

135 were small statistical differences favoring diclofenac for 2 of the end points.

136 possibility is that reactive metabolites of diclofenac form adducts with enterocyte macromolecules,

137 7 days, and artificial tears, ketorolac, and diclofenac four times daily for 14 days.

138 able predictions of uptake of fluoxetine and diclofenac from a sediment.

139 5 of the chemicals (bezafibrate, climbazole, diclofenac, furosemide, and hydrochlorothiazide), the me

140 r the removal of the anionic micropollutants diclofenac, gemfibrozil and ibuprofen from EfOM.

141 Cs (metoprolol, bezafibrate, clofibric acid, diclofenac, gemfibrozil, ibuprofen, ketoprofen, naproxen

142 This trial shows that rectal diclofenac given immediately after endoscopic retrograde

143 ients in the etoricoxib group and 323 in the diclofenac group had thrombotic cardiovascular events, y

144 s high, apoptosis-inducing concentrations of diclofenac (>100 microM).

145 he activity evoked by high concentrations of diclofenac has a profoundly distinct COX active site tha

146 Diclofenac has a risk very similar to rofecoxib, which w

147 Despite its widespread use, diclofenac has gastrointestinal liabilities common to no

148 cantly less common with etoricoxib than with diclofenac (hazard ratio [HR] 0.69, 95% CI 0.57-0.83; p=

149 nts per 100 patient-years for etoricoxib and diclofenac (hazard ratio [HR] = 0.84; 95% confidence int

150 The UGT2B7*2 allele was more common in diclofenac hepatotoxicity patients compared with hospita

151 ed 24-70 (mean, 50.8) years who had suffered diclofenac hepatotoxicity, 48 subjects (35 female) aged

152 e diclofenac metabolites are associated with diclofenac hepatotoxicity.

153 efficacy, safety, and local tolerability of diclofenac HPbetaCD administered as a local submucosal i

154 ficacy, safety, and relative tolerability of diclofenac HPbetaCD used locally as a submucosal injecti

155 ication ranged between 7.8 h (for 25 mg/1 mL diclofenac HPbetaCD) and 16 h (for 50 mg/1 mL diclofenac

156 iclofenac HPbetaCD) and 16 h (for 50 mg/1 mL diclofenac HPbetaCD).

157 ere randomized into 1 of 5 groups: 5 mg/1 mL diclofenac HPbetaCD, 12.5 mg/1 mL diclofenac HPbetaCD, 2

158 5 mg/1 mL diclofenac HPbetaCD, 12.5 mg/1 mL diclofenac HPbetaCD, 25 mg/1 mL diclofenac HPbetaCD, 50

159 12.5 mg/1 mL diclofenac HPbetaCD, 25 mg/1 mL diclofenac HPbetaCD, 50 mg/1 mL diclofenac HPbetaCD, or

160 , 25 mg/1 mL diclofenac HPbetaCD, 50 mg/1 mL diclofenac HPbetaCD, or 1 mL placebo.

161 revealed an enhanced removal of atorvastatin-diclofenac-hydrochlorothiazide (during the whole treatme

162 Nine cases of diclofenac hypersensitivity recorded by the Allergy Vigi

163 tive NSAIDs used in the development program (diclofenac, ibuprofen, and nabumetone).

164 0 days after initiation of NSAID (rofecoxib, diclofenac, ibuprofen, and naproxen compared with celeco

165 valdecoxib), as well as oral formulations of diclofenac, ibuprofen, naproxen, and a composite of all

166 bations, including acetaminophen, clozapine, diclofenac, imipramine, meclofenamic acid, and ticlopidi

167 Topical diclofenac in 2.5% hyaluronan inhibits basal cell carcin

168 ger term chronic health effects analysis for diclofenac in fish.

169 le prodrugs, producing significant levels of diclofenac in plasma within 15 min after oral administra

170 ay result in increased concentration of free diclofenac in plasma.

171 was greatly affected by in vitro exposure to diclofenac in T. scabrous also (IC50 = 6.86 +/- 1.4 muM)

172 sensor is selective and is able to quantify diclofenac in tap water.

173 analgesic activities comparable to those of diclofenac in the carrageenan-induced paw edema test and

174 h lesions caused by a high equimolar dose of diclofenac in the rat.

175 ttenuated by endothelial NO and abolished by diclofenac indicating the functional importance of B2R-i

176 st, the slow, time-dependent COX inhibitors (diclofenac, indomethacin, and flurbiprofen) were unaffec

177 compare the potencies of aspirin, celecoxib, diclofenac, indomethacin, lumiracoxib, meloxicam, naprox

178 flammatory drugs (NSAIDs), but in particular diclofenac, induce during this time period a COX activit

179 The diclofenac-induced activity also has the unusual propert

180 duction of COX-2 observed is responsible for diclofenac-induced COX enzyme activity, it is clear that

181 ntiating effect on allyl isothiocyanate- and diclofenac-induced currents of TRPA1 was isolated from t

182 Moreover, relative to COX-1 or COX-2, diclofenac-induced enzyme activity shows significantly r

183 Topical application of diclofenac inhibited tumor prostaglandin synthesis and r

184 Interestingly, diclofenac inhibition was unaffected by the mutation of

185 reatment of J774.2 cells with lower doses of diclofenac inhibits COX activity, indicating that diclof

186 ified Ser530 to inhibit the enzyme, and that diclofenac inhibits PGH(2) but not 15-hydroperoxyeicosat

187 The carboxylate of diclofenac interacts strongly with the CYP2C9 Arg108 sid

188 nd BFCOD) systems, especially in the case of diclofenac interference with BFCOD activity (IC50 = 15.7

189 fenac inhibits COX activity, indicating that diclofenac is a time-dependent, pseudoirreversible inhib

190 Diclofenac is a widely used nonsteroidal anti-inflammato

191 Postoperatively, diclofenac is found to be as effective an anti-inflammat

192 Although diclofenac is frequently found in aquatic systems, its d

193 Diclofenac is one of the most widely prescribed nonstero

194 he grafted molecular probe; conversely, when diclofenac is present in solution, a displacement equili

195 d binding affinity at lower pH suggests that diclofenac is protonated when bound to the enzyme.

196 nalysis showed that flutamide, troglitazone, diclofenac, isoniazid, and tamoxifen were reported to ha

197 , the latter method enables determination of diclofenac isotope ratios down to the sub-mugL(-1) range

198 and the nonsteroidal anti-inflammatory drug diclofenac, it has been shown that removal of the glucur

199 foundly distinct COX active site that allows diclofenac, its inducer, to be washed readily from its a

200 domethacin, sulindac, ketoprofen, ibuprofen, diclofenac, ketorolac, etc., cyclooxygenase inhibitors)

201 ts increased in the order of carbamazepine < diclofenac < fluoxetine < orlistat.

202 14)C, increased in the order carbamazepine < diclofenac < fluoxetine and orlistat.

203 ed that the dissipation half-lives (DT50) of diclofenac (<0.1-1.4 days), bezafibrate (<0.1-4.8 days),

204 8, which determine the formation of reactive diclofenac metabolites and in ABCC2 encoding the transpo

205 o the formation and accumulation of reactive diclofenac metabolites are associated with diclofenac he

206 ex vivo and in vivo, while others, including diclofenac metabolites, were agonists.

207 Rectal diclofenac might provide a simple, cheap alternative but

208 e events were more common when patients took diclofenac + misoprostol (P = 0.046).

209 Differences favoring diclofenac + misoprostol over acetaminophen were greater

210 vement in the primary outcomes were seen for diclofenac + misoprostol than for acetaminophen (P < 0.0

211 mprovements in pain scores over 6 weeks with diclofenac + misoprostol than with acetaminophen, althou

212 Diclofenac + misoprostol was rated as "better" or "much

213 tients underwent endoscopy (celecoxib n=212, diclofenac n=218).

214 ngle 75-mg (3 mL) intramuscular injection of diclofenac (n = 27) or similarly administered 3 mL of sa

215 wild bream and roach living in a lake where diclofenac, naproxen, and ibuprofen are present as pollu

216 The observed bile concentrations of diclofenac, naproxen, and ibuprofen in bream ranged from

217 The potencies of diclofenac, naproxen, rofecoxib, and salicylate, but not

218 Given the risks of a direct challenge to diclofenac, OC to aspirin should be performed first to e

219 to 8.40]) and celecoxib versus ibuprofen or diclofenac (odds ratio, 0.77 [CI, 0.40 to 1.48]).

220 es and distinct voltage-dependent effects of diclofenac on channel activation and deactivation observ

221 ted the effects of celecoxib, rofecoxib, and diclofenac on ionic currents and calcium signaling in va

222 The opposite effects of diclofenac on KCNQ4 and KCNQ5 could not be attributed to

223 ve inhibitors (nimesulide, flurbiprofen, and diclofenac) on the proportions and stability of the two

224 esthetised rats, the PG synthesis inhibitors diclofenac or indomethacin reduced muscle vasodilatation

225 icantly reduced sensitivity to inhibition by diclofenac or other competitively acting nonsteroid anti

226 given a suppository containing either 100 mg diclofenac or placebo.

227 epafenac (0.01%, 0.03%, 0.1%, or 0.5%), 0.1% diclofenac, or 0.5% ketorolac tromethamine in mice with

228 Inhibitors of COX (naproxen, diclofenac, or ibuprofen) increased bronchoconstriction

229 otic leakage, and were treated with vehicle, diclofenac, or prostaglandin E2 (PGE2), the most importa

230 d coculture plus or minus the COX-inhibitor, Diclofenac, or synthetic PGE(2) in the absence of HNSCC.

231 ients received 1000 mg paracetamol and 50 mg diclofenac, orally, to be continued on an 8-h schedule f

232 d statistical criteria, to that of 150 mg of diclofenac per day in this 1-year study.

233 ute pancreatitis as well as the finding that diclofenac prevents endoscopic retrograde cholangiopancr

234 n explorative survey, analysis of commercial diclofenac products showed significant differences in ca

235 Although diclofenac ranks among the most frequently detected phar

236 onfidence interval [95% CI] -0.20, 3.01) and diclofenac (RD 6.07, 95% CI -0.02, 12.15).

237 Diclofenac reduced adenosine-evoked NO release by ~50 %

238 lind controlled trial to determine if rectal diclofenac reduces the incidence of pancreatitis followi

239 Diclofenac residues and renal disease were reproduced ex

240 whole-cell KCNQ currents with properties and diclofenac responses characteristic of overexpressed het

241 dac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumin, dexamethasone, celeco

242 dac, phenylbutazone, naproxen, indomethacin, diclofenac, resveratrol, curcumin, dexamethasone, celeco

243 The combination of diclofenac's uptake potential, effects on kidney nephron

244 and 293 decreased catalytic activity toward diclofenac, (S)-warfarin, and pyrene in a substrate-inde

245 Administration of diclofenac shifted the experimental renogram curves to t

246 Diclofenac should be removed from EMLs.

247 rmed but did not sorb significantly, whereas diclofenac showed both degradation and sorption.

248 a albicans biofilms grown in the presence of diclofenac showed increased susceptibility to caspofungi

249 Patients using diclofenac showed no higher incidence of serious liver d

250 tly less CNV, whereas eyes treated with 0.1% diclofenac showed no significant difference.

251 After taking diclofenac slow-release 75 mg twice a day (with omeprazo

252 ugs, such as ketorolac tromethamine 0.5% and diclofenac sodium 0.1%, offer comparable efficacy to cor

253 flammatory agents ketorolac tromethamine and diclofenac sodium augmented the effect of BMP2 on cornea

254 Diclofenac sodium is a widely used nonsteroidal anti-inf

255 sought to determine the effect of the NSAID diclofenac sodium on monoamine turnover in brain induced

256 Series II: Diclofenac sodium ophthalmic solution 0.1% or a placebo

257 After diclofenac sodium salt solution injection, drug levels d

258 AUC was significantly higher at MN+diclofenac sodium sites vs. placebo, suggesting slower r

259 Rabbit eyes were injected with either diclofenac sodium solution (0.3 mg) or diclofenac acid s

260 s indicated the inability of a 10-mg dose of diclofenac sodium solution to sustain drug levels in the

261 debridement, whereas corneas pretreated with diclofenac sodium swelled only 19.2 +/- 3.1 microm (n =

262 th dexamethasone, ketorolac tromethamine, or diclofenac sodium when used in the presence, but not in

263 N treatment and daily topical application of diclofenac sodium.

264 compared to 2.9 and 0.9 hours observed with diclofenac sodium.

265 th dexamethasone, ketorolac tromethamine, or diclofenac sodium.

266 omethamine; group III, 0.5% cidofovir + 0.1% diclofenac sodium; and group IV, control + artificial te

267 ssigned oral celecoxib 200 mg twice daily or diclofenac SR 75 mg twice daily for 24 weeks.

268 exceeded the predicted no-effect levels for diclofenac, sulfamethoxazole and carbamazepine, respecti

269 dicle ligature or anal-canal dressing, and a diclofenac suppository was administered at the end of th

270 The elimination half-life of diclofenac suspension was 24 and 18 days in vitreous and

271 ic acid, bisphenol A, gemfibrozil, naproxen, diclofenac, technical 4-nonylphenol, and 4-tert-octylphe

272 After diclofenac, the A(1) receptor agonist CCPA evoked no vas

273 For diclofenac, the pathway leading to the experimentally ob

274 lestradiol (EE2), 17beta-estradiol (E2), and diclofenac throughout European rivers.

275 ovocation test was performed with aspirin or diclofenac to categorize the patients according to the E

276 pepsia, was nearly three times higher in the diclofenac-treated group than in the celecoxib group (16

277 t oral exposure and through feeding vultures diclofenac-treated livestock.

278 binds into the membrane showed that chronic diclofenac treatment of fibroblasts results in marked mo

279 Diclofenac treatment resulted in the formation of drug a

280 nct COX-2 populations in response to chronic diclofenac treatment.

281 Finally, the low molecular weight compound diclofenac was bound to the surface to be used as model

282 Diclofenac was by far the most commonly used NSAID, with

283 nts was due to the parent compounds but that diclofenac was degraded in the test system so uptake was

284 Diclofenac was found in five of the bream and roach samp

285 Diclofenac was listed on 74 national EMLs, naproxen on j

286 Diclofenac was not found to modulate the expression of g

287 e at positive polarity; and 4'- or 5-hydroxy diclofenac was not separated by a generic UPLC method.

288 Retardation of diclofenac was reflected in additional (15)N sorption is

289 n observed (for fish exposed to 25 mug L(-1) diclofenac) was within the therapeutic range for humans.

290 t, the inhibitory effects of indomethacin or diclofenac, which also inhibit both cyclo-oxygenase-1 an

291 imit is ca. 20 fM, corresponding to 6pgL(-1) diclofenac, which is competitive compared to other label

292 e nonsteroidal antiinflammatory drug (NSAID) diclofenac, which is the most commonly used drug to reli

293 nzyme 2C5dH catalyze the 4'-hydroxylation of diclofenac with apparent K(m) values of 80 and 57 microM

294 Concurrent treatment of ketorolac or diclofenac with cidofovir did not diminish its antiviral

295 oricoxib are similar to those in patients on diclofenac with long-term use of these drugs.

296 ion of the crystal structure of a complex of diclofenac with murine COX-2 demonstrates that diclofena

297 170 women with self-administered paracetamol-diclofenac with or without TAP blocks.

298 elate residues of the anti-inflammatory drug diclofenac with renal failure.

299 flammatory and analgesic activity similar to diclofenac, with a lower frequency of upper gastrointest

300 nts and partial elimination for orlistat and diclofenac, with greater than 30% of the (14)C remaining